Synthesis, DFT Studies, Molecular Docking, and In Vitro Cytotoxic Evaluation of Schiff Bases as Potential Anti-Breast Cancer Agents
DOI:
https://doi.org/10.56714/bjrs.52.1.17Keywords:
Benzothiazole-derived, Schiff base, Breast cancer, Molecular docking, MTT assayAbstract
In this study, three benzothiazole derived Schiff bases were prepared in good yield. The 1HNMR, 13CNMR, 2DNMR, mass and FTIR spectroscopy were used to characterize the suggested structures. Molecular docking studies of the prepared Schiff bases 1-3 against two aromatase inhibitor receptors, 5JL6 and 5JL7, were conducted. Binding energies were calculated, within the range -8.6 to -9.3 kcal/mol. Schiff bases 1 exhibited the best binding energies against receptors 5JL6 and 5JL7, at -8.9 and -9.3 kcal/mol respectively. The results of the in vitro cytotoxicity assay using the MTT against the MCF7 breast cancer cell line at various concentrations of the prepared compounds were consistent with the molecular docking results. The IC50 value of compound 1 was 33.96 µM against MCF-7, which is the lowest and closest to that of cisplatin 27.0 µM, which served as a reference. The DFT calculations showed that compound 1 had the lowest energy gap compared to the other prepared compounds. The theoretical polarizability calculations also revealed that compound 1 exhibited the highest polarizability value at 2.024 x10-24 esu, while compounds 2 and 3 had values at 1.933 x10-24 and 1.845 x10-24 esu, respectively
Downloads
References
[1] F. Laversanne, M. Sung, H. Ferlay, J. Siegel, R. L. Soerjomataram, I., and A. Jemal, “Global cancer statistics : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”, CA: A Cancer Journal for Clinicians, vol. 74, issue 3, pp. 229–263, 2022.DOI: https://doi.org/10.3322/caac.21834Digital Object Identifier (DOI) DOI: https://doi.org/10.3322/caac.21834
[2] N. Harbeck, F. Penault-Llorca, J. Cortes, M. Gnant, N. Houssami, P. Poortmans, K. Ruddy, J. Tsang, and F. Cardoso, “Breast cancer,” Nature Reviews Disease Primers, vol. 5, issue 1, Article 66, 2019. DOI: https://doi.org/10.1038/s41572-019-0111-2. DOI: https://doi.org/10.1038/s41572-019-0111-2
[3] A. M. Dhumad, A. M. Jassim, R. A. Alharis, F. A. Almashal, “Design, cytotoxic effects on breast cancer cell line (MDA-MB 231), and molecular docking of some maleimide-benzenesulfonamide derivatives,” Journal of the Indian Chemical Society, vol. 98, issue 4, pp. 100055, 2021. DOI: https://doi.org/10.1016/j.jics.2021.100055. DOI: https://doi.org/10.1016/j.jics.2021.100055
[4] A. Subramanian, M. Salhab, K. Mokbel, “Oestrogen producing enzymes and mammary carcinogenesis: a review,” Breast Cancer Res Treat, vol. 111, pp.191–202 2008. DOI: https://doi.org/10.1007/s10549-007-9788-0 DOI: https://doi.org/10.1007/s10549-007-9788-0
[5] S. Patel “Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: a comprehensive review,” J Steroid Biochem Mol Biol, vol. 168, pp. 19–25, 2017. DOI:https://doi.org/10.1016/j.jsbmb.2017.01.009 DOI: https://doi.org/10.1016/j.jsbmb.2017.01.009
[6] S. Zhang Q., S. Jia, X. Li, R. Hu, Z. Luo, J. Wang and H. Xi, “Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network,” Expert Opinion on Drug Safety, vol. 24, issue 3, pp. 315–324, 2025. DOI: https://doi.org/10.1080/14740338.2024.2424443 DOI: https://doi.org/10.1080/14740338.2024.2424443
[7] A. Edith Perez, “The balance between risks and benefits: Long-term use of aromatase inhibitors,” European Journal of Cancer Supplements,Vol. 4, Issue 9, pp. 16-25, 2006. DOI: https://doi.org/10.1016/j.ejcsup.2006.06.003. DOI: https://doi.org/10.1016/j.ejcsup.2006.06.003
[8] M. Shahzad Lodhi, M. Bibi, G. Kök, H. Muzzammel Rehman, S. Sharif, Y. Salman, M. Sajjad, E. Ali, R. Ullah, G. Ali, A. Alotaibi, E. Halay, “Synthesis, characterization, and In vitro Anti-cancer Studies of Triazine Core Schiff Base against Breast Cancer,” Journal of Molecular Structure, vol. 1339, pp. 142343, 2025.DOI: https://doi.org/10.1016/j.molstruc.2025.142343. DOI: https://doi.org/10.1016/j.molstruc.2025.142343
[9] P. Kalaria, S.Karad, D.Raval, “A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery,” European Journal of Medicinal Chemistry, vol. 158, pp. 917-936, 2018. DOI: https://doi.org/10.1016/j.ejmech.2018.08.040. DOI: https://doi.org/10.1016/j.ejmech.2018.08.040
[10] D. Qassim Kamil, A. Hussein Wasmi, W. Abed AL Hassan Alhaidry, M. Kassim Al-Hussainawy, H. Ali Kadhim Kyhoiesh, “Synthesis, molecular docking, ADMET profiling, and anti-PC3 activity of new Schiff base derivatives,” Results in Chemistry, vol. 12, pp.101916, 2024. DOI:https://doi.org/10.1016/j.rechem.2024.101916 DOI: https://doi.org/10.1016/j.rechem.2024.101916
[11] K. Gupta, A. Kumar Sirbaiya, V. Kumar, M. Azizur Rahman, “Current Perspective of Synthesis of Medicinally Relevant Benzothiazole based Molecules: Potential for Antimicrobial and Anti-InflammatoryActivities,” Mini-Reviews in Medicinal Chemistry; Vol. 22, Issue 14, 2022. DOI: https://doi.org/10.2174/1389557522666220217101805. DOI: https://doi.org/10.2174/1389557522666220217101805
[12] F. Abdulkareem Almashal, M. Qasim Mohammed, Q. M. Ali Hassan, C.A. Emshary, H.A. Sultan, A. Muala Dhumad, “Spectroscopic and thermal nonlinearity study of a Schiff base compound,” Optical Materials, Vol. 100, pp. 109703, 2020. DOI: https://doi.org/10.1016/j.optmat.2020.109703. DOI: https://doi.org/10.1016/j.optmat.2020.109703
[13] P. Marinova, P. Tamahkyarova, “Synthesis, Investigation, Biological Evaluation, and Application of Coordination Compounds with Schiff Base—A Review” Compounds., vol. 5, issue 2, pp.14, 2025. DOI: https://doi.org/10.3390/compounds5020014 DOI: https://doi.org/10.3390/compounds5020014
[14] K. Francis, K. Mawa, L. Ekossias, B. Digre, N. Camille, and G. Stephane, “Quantitative Structure Activity Relationship (QSAR) Anticancer Modeling of the MCF-7 Cell Line of Phthalocyanine Derivatives,” International Research Journal of Pure and Applied Chemistry, vol. 26, issue 6, pp. 98-109, 2025. DOI: https://doi.org/10.9734/irjpac/2025/v26i6962. DOI: https://doi.org/10.9734/irjpac/2025/v26i6962
[15] R. Verma and C. Hansch, “Cytotoxicity of Organic Compounds against Ovarian Cancer Cells: A Quantitative Structure−Activity Relationship Study,” Molecular Pharmaceutics vol. 3, issue 4, pp. 441-450, 2006. DOI: https://doi.org/10.1021/mp050110i DOI: https://doi.org/10.1021/mp050110i
[16] P. Duan, Sh. Li, N. Ai, L. Hu, W. Welsh, and G. You, “Potent Inhibitors of Human Organic Anion Transporters 1 and 3 from Clinical Drug Libraries: Discovery and Molecular Characterization,” Molecular Pharmaceutics, vol. 9, issue 11, pp. 3340-3346, 2012. DOI: https://doi.org/10.1021/mp300365t DOI: https://doi.org/10.1021/mp300365t
[17] A. Majeed Jassem, A. Muala Dhumad, J. Khudhair Salim, H.Abdalsamad Jabir, “An alternative technique for cyclization synthesis, in vitro anti-esophageal cancer evaluation, and molecular docking of novel thiazolidin-4-one derivatives,” Journal of Molecular Structure, vol. 1280, pp. 135079, 2023. DOI: https://doi.org/10.1016/j.molstruc.2023.135079. DOI: https://doi.org/10.1016/j.molstruc.2023.135079
[18] H. Tandon, P. Ranjan, T. Chakraborty, and V. Suhag, “ Polarizability: a promising descriptor to study chemical–biological interactions,” Mol Divers, vol. 25, pp. 249–262, 2021. DOI: https://doi.org/10.1007/s11030-020-10062-w. DOI: https://doi.org/10.1007/s11030-020-10062-w
[19] A. M. Jassem, and A. M. Dhumad, “Synthesis, Antimicrobial Activity, Anti‐HIV Activity, and Molecular Docking of Novel 5‐, 6‐ and 7‐Membered Ring (1 H ‐Pyrrol‐2‐yl)aminolactams,” Chemistry Select, vol. 6, issue 10, pp. 2641-2647, 2021. DOI: https://doi.org/10.1002/slct.202004755 DOI: https://doi.org/10.1002/slct.202004755
[20] R. Jerome de, B. Guillaume, B. Ralf, L. Marc, “Molecular docking as a popular tool in drug design, an in silico travel,” Advances and Applications in Bioinformatics and Chemistry, vol. 9, pp. 1-11, 2016. DOI: https://doi.org/10.2147/AABC.S105289. DOI: https://doi.org/10.2147/AABC.S105289
[21] Z. K. Shaheen, A. A. Al-Ali, S. A. Al-Asadi, “Anti-cancer activity of lavender oil and Newcastle disease virus on human glioblastoma: an in vitro study,” Journal of Basrah Researches (Sciences), vol. 49, issue 1, pp.1-12, 2023. DOI: https://doi.org/10.56714/bjrs.49.1.1 DOI: https://doi.org/10.56714/bjrs.49.1.1
[22] Fatima A. Ahmed and Dakhil Mutlaq, “Synthesis and anti-breast cancer activity of some succinimide derivatives via Michael addition reaction: arylhydrazide to maleimides,” Journal of Basrah Researches (Sciences), vol. 50, issue 2, pp.28-197, 2024. DOI: https://doi.org/10.56714/bjrs.50.2.24. DOI: https://doi.org/10.56714/bjrs.50.2.24
[23] Z. Saleem Zami, M. Mohammed Nasri, A. Abd-Aljaleel Nsaif, N. AL-Huda Salah AL-Zuhairy , Kh. Fahim Muhsin, Sh. Mazin Abdulsahib Al-khafaji, “Therapeutic Role of Coenzyme Q10 in Male Infertility: A Semen Analysis-Based Study,” Journal of Basrah Researches (Sciences), vol. 50, issue 2, pp.141, 2025. DOI: https://doi.org/10.56714/bjrs.51.2.11. DOI: https://doi.org/10.56714/bjrs.51.2.11
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Journal of Basrah Researches (Sciences)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This journal is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Under this license, users are permitted to read, download, copy, distribute, print, search, link to the full texts of articles, and create derivative works, including for commercial purposes, provided that appropriate credit is given to the original author(s) and the source.
Authors retain the copyright of their published work, while granting the Journal of Basrah Researches Sciences (JBRS) the right of first publication. Proper attribution must include the article title, author name(s), journal name, DOI, and a link to the Creative Commons license.
